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Introduction: Beta blockers have proven benefit in the treatment of
chronic heart failure. In CIBIS II, the total mortality and the risk of sudden
death were reduced in patients treated with Bisoprolol compared to placebo
respectively 11.8% vs. 17.3%, p <0001 and 3.6 vs 6.3%, p < 002 regardless
of age, NYHA class and co-morbidities. In our study a similar effect of Biso-
prolol in chronic heart failure with right ventricular dysfunction is proposed.
Material and methods: This study examined the short-term effect of Biso-
prolol on right ventricular function in patients with chronic heart failure with
right ventricular dysfunction. A cohort of 60 patients with chronic heart failure
with right ventricular dysfunction who were not taking beta-blockers has been
previously studied prospectively. The RVEF and LVEF were measured at
baseline and followed for 6 months by Doppler echocardiography. Various
parameters of the right ventricular function were measured: RVEF, fractional
shortening surface, TAPS, Doppler tissue S’DTI tricuspid ring and RV Tei
index. The significance level was set at 5%. The maximum dose of Bisoprolol
was titrated during four monthly visits by a preestablished protocol to a target
dose of 10mg / day.
Results: The average age of participants was 65.7±16.3 years, RVEF at
6 months was 25.6±5.2 and the baseline was 20.8±6.4. The maximum dose of
Bisoprolol was 5.7±3.7mg / day. At 6 months the RVEF increased signifi-
cantly from 7.9% (confidence interval 95%, 03-10.02%, p <0.0001) and left
ventricular ejection fraction also increased significantly from 7.5% (range
95% confidence, 4.0-11.9%, p <0.0003). All parameters of right ventricular
function were significantly improved.
Conclusion: Treatment with Bisoprolol in chronic heart failure with right
ventricular dysfunction at 6 months resulted in a significant improvement in
right ventricular ejection fraction, which in parallel with the improvement of
left ventricular ejection fraction. 
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ExtraCorporeal Life Support (ECLS) restores hemodynamic stability in
patients with severe cardiocirculatory failure. However, this circulatory assis-
tance technique has its limits, and the most strongly feared is left ventricular
distention, of which the potentially serious consequences range from acute
pulmonary edema (APE) to left intraventricular thrombosis. Our hypothesis is
that in patients in refractory cardiogenic shock and with laminar flow under
peripheral V-A ECLS, IABP use could help to diminish the incidence of acute
pulmonary edema (APE). 
Methods:The clinical evolution of patients with laminar flow under
peripheral V-A ECLS who did not receive IABP (group A) has been com-
pared to the clinical evolution of patients who received IABP as a means of
APE prevention under peripheral V-A ECLS, while also being subjected to
laminar flow under peripheral V-A ECLS (group B). A logistic regression
model was used to identify the factors associated with occurrence of severe
and symptomatic APE. 
Results: Between December 2007 and 2012, 90 patients were subjected to
laminar flow under peripheral V-A ECLS that had been implanted subsequent
to cardiogenic shock. Mortality and mechanical ventilation duration was not
significantly different in either of the two groups. However, clinical APE occur-
rence was far less frequent in group B (35.1% vs. 88.6% p<0.0001). Study of
the radiologic score showed that pulmonary infiltrate was greater in group A
(p≤0,001). Centralized pulmonary edema was likewise more frequent in group
A (44.6% vs. 5.9%, p<0.0001). Multivariate analysis showed that the non-asso-
ciation of IABP with peripheral V-A ECLS (Odds Ratio [OR]=18.87) was an
independent factor associated with the incidence of severe symptomatic APE.
Conclusion: Association of IABP and peripheral V-A ECLS can be consi-
dered therapeutically efficient in prevention of severe symptomatic pulmonary
edema under peripheral V-A ECLS, even though confirmation would require
a randomized study.
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Aims: Part of over 80-year-old heart failure (HF) patients is increasing. These
patients are poorly studied. The present study undertook a ‘real-life’ analysis of
various aspects of the prognosis of over 80-year-old HF patients in France.
Methods and results: Analysis was based on the EGB (“Echantillon
Généraliste des Bénéficiaires”) database, a continuously updated representa-
tive sample of the population covered by the French national health insurance
system. A cohort of adult patients with a first admission for HF was created
between 2009 and 2011 and followed until June 2013 for survival analysis.
Over 80-year-old patients represented 53% (n=969/1825) of hospitalizations
for HF. In octogenarians, in-hospital mortality was 10.9% [9.6-12.2] and mean
12 –, and 24-months survival 62.3% (range, 59.1-65.4) and 48.2% (44.8-51.5).
Only prescription levels for beta-blockers (BB) (p=0.02) increased during the
follow-up period. Only 5% of patients received at discharge an optimal treat-
ment [association of angiotensin converting enzyme inhibitors/angiotensin
receptor blockers (ACEi/ARB) +BB+mineralocorticoid receptor antagonists
(MRA)]. During this period there was no increase of ACEi and ACEi/
ARB+BB+MRA prescription at discharge (p=0.48 and p=0.87, respectively).
On multivariate analysis, atrial fibrillation [HR: 0.77(0.65–0.91), p=0.003],
female gender [0.80(0.67–0.95), p=0.01] and the associations ACEi/
ARB+BB+MRA [0.49(0.29–0.85), p=0.01] and ACEi/ARB+BB [0.54(0.43–
0.68), p<0.001] were associated with improved survival, in contrast to denu-
trition [1.64(1.27–2.13), p<0.001] and cardiogenic shock at admission
[3.11(1.78–5.46), p<0.001]. 
Conclusion: Octogenarians HF patients are poorly managed and treated
according to international guidelines despite the clinical benefit of such drugs
confirmed in this un-selected cohort with several comorbidities. 
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